Scientific programme – details

Tuesday, 21 October 2008

Opening Ceremony **Room ABC**

13:00–13:10 Opening remarks

M. Piccart	EORTC
J. Doroshow	NCI
W.N. Hait	AACR

Michel Clavel lecture **Room ABC**
Chair: P. Schöffski (Leuven, Belgium) Abstract number

13:15–14:00 No risk, no fun 1
J. Verweij (Rotterdam, The Netherlands)

Keynote lecture **Room ABC**
Chair: J. Doroshow (Bethesda, USA) Abstract number

14:00–14:45 IGF-I as an emerging target 2
D. Yee (Minneapolis, USA)

Plenary session 1 **Room ABC**
Abstract number

15:15–17:00 **Molecular targets – state of the science A**
Chairs: C.J.A. Punt (Nijmegen, The Netherlands) and A.J. Murgo (Bethesda, USA)

15:15 RET inhibition: therapeutic implications in thyroid cancer 3
D.G. Pfister (New York, USA)

15:40 C-Met as a target in clinical oncology; rationale and current achievements 4
F.A.L.M. Eskens (Rotterdam, The Netherlands)

16:05 Biological roles of PI 3-kinase isoforms 5
B. Vanhaesebroeck (London, United Kingdom)

16:30 Notch as a potential therapeutic target in cancer 6
L. Miele (Illinois, USA)

Wednesday, 22 October 2008

Workshop 1 **Room A**

		Abstract number
08:00–09:45	**Animal models in drug development** Chairs: J.L. Abbruzzese (Houston, USA) and G. Adolf (Vienna, Austria)	
08:00	Developing combination therapies for hormone-refractory prostate cancer in a pre-clinical mouse model of the disease *C. Abate-Shen (New York, USA)*	7
08:25	Pitfalls for cancer drug discovery with "genetic" animal models *E. Sausville (Baltimore, USA)*	8
08:50	How naturally occurring cancers in dogs can inform the drug development path *C. Khanna (Bethesda, USA)*	9
09:15	Imaging signaling pathways in animal models *A. Rehemtulla (Ann Arbor, USA)*	10

Workshop 2 **Room B**

		Abstract number
08:00–09:45	**Paediatric Oncology** Chairs: M. Smith (Rockville, USA) and G. Vassal (Villejuif, France)	
08:00	Update on the application of the EU paediatric regulation *R. Herold (London, United Kingdom)*	11
08:20	The Pediatric Preclinical Testing Program (PPTP): changing the paradigm for drug development *P. Houghton (Memphis, USA)*	12
08:40	KidsCancerKinome: a EU-FP6 project for preclinical kinase inhibitor evaluation as a tool to prioritize compounds for paediatric development *H. Caron (Amsterdam, The Netherlands)*	13
09:00	Early phase drug development in the Children's Oncology Group *P.C. Adamson (Philadelphia, USA)*	14
09:20	Early drug development in the childrens' clinics in Europe *G. Vassal (France)*	15

Workshop 3 **Room C**

		Abstract number
08:00–09:45	**Pharmacogenomics – where are we now?** Chairs: W.D. Figg (Bethesda, USA) and R.E. Parchment (Frederick, MD, USA)	
08:00	Pharmacogenomics of anticancer drug disposition: we aren't there yet *A. Sparreboom (Memphis, USA)*	16
08:25	Bioinformatics – from the bench to the bedside and back *G. Rajagopal (New Brunswick, USA)*	17
08:50	Pharmacogenomics in colon cancer: Fantasy or Reality *H. Lenz (Los Angeles, USA)*	18

09:15 High throughput genotyping and its possible applications in pharmacoepidemiology 19
D.G. Cox (Lyon, France)

Workshop 4 **Room A**

Abstract number

10:15–12:00 **Phase 0 trials – are they necessary?**
Chairs: E. Leo (Beerse, Belgium) and J. Doroshow (Bethesda, USA)

10:20 Phase 0 microdosing studies as part of the learn/confirm approach to drug development 20
C. Garner (Heslington York, United Kingdom)

10:45 Use of phase 0-changes in cancer drug development 21
J. Collins (Rockville, USA)

11:10 Implementation of phase 0 trials 22
J.H.M. Schellens (Amsterdam, The Netherlands)

11:35 Industry perspective 23
G. Gordon (USA)

Workshop 5 **Room B**

Abstract number

10:15–12:00 **Targeting the CYP pathway**
Chairs: A.M. Burger (Detroit, MI, USA) and G. Demetri (Boston, USA)

10:15 The evolution of CYPs from metabolising enzymes to potential targets in cancer therapy development 24
L.H. Patterson (Bradford, United Kingdom)

10:40 CYP-activated prodrugs as chemotherapeutics 25
R. Plummer (Newcastle upon Tyne, United Kingdom)

11:05 Selective CYP17 inhibition with abiraterone acetate (AA) in castration resistant prostate cancer (CRPC): the Royal Marsden Hospital experience 26
A. Reid (London, United Kingdom)

11:30 Novel atypical retinoic acid metabolism blocking agents (RAMBAs)/CYP26 inhibitors for breast cancer therapy 27
V.C.O. Njar (Baltimore, USA)

Workshop 6 **Room C**

Abstract number

10:15–12:00 **Design and conduct of phase II trials for targeted agents**
Chairs: J.A. Zwiebel (Rockville, USA) and G. Pond (Ontario, Canada)

10:15 Adaptive phase II trials 28
D. Berry (USA)

10:40 Parallel phase II trials – European perspective 29
D. Lacombe (Brussels, Belgium)

11:05 Patient enrichment strategy in phase II 30
J. De Bono (United Kingdom)

11:30 Using biomarkers in phase II studies 31
J. Tabernero (Barcelona, Spain)

Keynote Lecture **Room ABC**
Chair: P. Schöffski (Leuven, Belgium) Abstract number

14:00–15:00 New response evaluation criteria in solid tumors: revised RECIST guideline version 1.1 32
E. Eisenhauer (Kingston, Canada)

Plenary session 2 **Room ABC**
Abstract number

15:00–16:00 **Proffered paper session**
Chairs: L.J. Helman (Bethesda, USA) and J.C. Soria (Villejuif, France)

15:00 Preclinical evaluation of 64Cu labeled bevacizumab by PET/CT imaging in tumor models 33
Z. Wang (Mattawan, USA)

15:15 Advantages of a modified continual reassessment method (CRM) for dose finding studies: experience in ongoing phase I trials with ABT-263 34
Y. Chiu (Abbott Park, USA)

15:30 Clinical attrition rates for kinase inhibitors in oncology 35
I. Walker (London, United Kingdom)

15:45 A Phase I single dose escalation study of the novel Polo-like kinase 1 inhibitor BI 6727 in patients with advanced solid tumours 36
P. Schöffski (Leuven, Belgium)

Plenary session 3 **Room ABC**
Abstract number

16:30–18:15 **Molecular targets – state of the science B**
Chairs: P. Ivy (Rockville, USA) and A. Awada (Brussels, Belgium)

16:30 Drugging the cancer chaperone Hsp90: From chemical biology with natural products to active drugs in the clinic 37
P. Workman (Sutton, United Kingdom)

16:55 Bortezomib therapy of multiple myeloma 38
K. Anderson (Boston, USA)

17:20 Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer 39
K. Sakamoto (Los Angeles, USA)

17:45 Role of autophagy in cancer and therapy 40
E. White (Piscataway, USA)

Poster Sessions

Angiogenesis Abstract number

DCE-MRI endpoints reveal decreased tumor vascularity in patients with liver metastases: a Phase I dose escalating study with IMC-1121B 41
N.J. Serkova, J. Spratlin, S.G. Eckhardt, B. Milestone, E.G. Chiorean, H. Youssoufian, F. Fox, E. Rowinsky, R.B. Cohen

NPI-2358 (a novel vascular disrupting agent) Phase 1 dose escalation trial with an RP2D cohort 42
M. Mita, M.A. Spear, L.K. Yee, K.P. Papadopoulos, E.I. Heath, M. Pilat, O. Romero, G.K. Lloyd, A. Mita, P. LoRusso

Animal models Abstract number

Biomarkers Abstract number

Chemoprevention Abstract number

Drug delivery Abstract number

Drug screening Abstract number

Heat shock proteins Abstract number

Hormonal agents Abstract number

Metastasis and invasion Abstract number

Natural products and marine compounds Abstract number

Paediatric – early drug development Abstract number

Phamacogenomics Abstract number

Phase II Abstract number

PI3Kinase Abstract number

Proteasome Abstract number

Thursday, 23 October 2008

Plenary session 4 **Room ABC**

Abstract number

08:00–09:45 **Targeting autophagic pathways**
Chairs: N. Zaffaroni (Milan, Italy) and R.S. DiPaola (New Brunswick, USA)

08:05 Oncogenes and tumor suppressor genes control autophagy 239
G. Kroemer (Villejuif, France)

08:30 Role of autophagy in cancer resistance 240
S. Kondo (Chiba, Japan)

08:55 Novel therapeutic targets within the autophagic pathway 241
W.N. Hait (USA)

09:20 Targeting apoptosis-resistant cancer cells through autophagic cell death 242
B. Lu (Nashville, USA)

Plenary session 5 **Room ABC**

Abstract number

10:15–12:00 **Molecular targets – state of the science C**
Chairs: M.J.A. de Jonge (Rotterdam, The Netherlands) and D.R. Spriggs (New York, USA)

10:20 Aurora kinase inhibitors: more than one opportunity? 243
B. Laffranchi (Nerviano (Milano), Italy)

10:45 Polo-like kinase inhibition in oncology: from bench to bedside 244
P. Schöffski (Leuven, Belgium)

11:10 PARP inhibitors in cancer treatment 245
H. Calvert (Newcastle-upon-Tyne, United Kingdom)

11:35 Targeting Her: Can resistance to EGFR inhibitors be overcome? 246
B. Burtness (Philadelphia, USA)

Plenary session 6 **Room ABC**

Abstract number

14:30–16:00 **Proffered paper session**
Chairs: J. Tomaszewski (Bethesda, USA) and T. Lawrence (Ann Arbor, USA)

14:30 First-in-Human study of the First-in-Class Hdm2 inhibitor JNJ-26854165 1LB
J. Tabernero (Barcelona, Spain)

14:45 A phase II study of abiraterone acetate plus prednisone in patients with castration resistant prostate cancer (CRPC) and no prior therapy with ketoconazole 2LB
C. Ryan (San Francisco, USA)

15:00 BRAF V600E confers resistance to cetuximab or panitumumab in metastatic colorectal cancer 247
F. Di Nicolantonio (Candiolo (Torino), Italy)

15:15 Notch pathway: a potential new target for the treatment of paediatric ependymomas 248
C. Dantas-Barbosa (Villejuif, France)

Plenary session 7 **Room ABC**

Abstract number

16:30–18:15 **Targeting protein translation and protein–protein interaction in cancer**
Chairs: Y. Pommier (Bethesda, USA) and H. Newell (Newcastle Upon Tyne, UK)

Poster Sessions

Apoptosis, necrosis, autophagy Abstract number

Aurora kinase Abstract number

Cyclins and CDK's Abstract number

Gene therapy and antisense approaches Abstract number

Her Abstract number

mTOR Abstract number

New molecular targets Abstract number

Phase I Abstract number

Polo kinases Abstract number

Protein – protein interaction Abstract number

Telomerase-targeting agents Abstract number

Tubulin-interacting agents Abstract number

Friday, 24 October 2008

Plenary session 8 **Room ABC**

Abstract number

08:00–09:45 **RNA based technologies for target identification, validation and treatment**
Chairs: E.H. Rubin (New Jersey, USA) and P. Ho (Collegeville, USA)

08:00 Development of practical delivery systems for therapeutic small RNAs 456
A. Aigner (Marburg, Germany)

08:25 Identifying mechanisms of drug resistance using large scale genetic screens 457
R. Bernards (Amsterdam, The Netherlands)

08:50 High-throughput RNAi screening using cell microarray technology 458
O. Kallioniemi (Helsinki, Finland)

09:15 microRNA and therapeutic applications 459
D. Cohen (North Brunswick, USA)

Plenary session 9 **Room ABC**

Abstract number

10:15–12:00 **Imaging molecular targets**
Chairs: J.L. Tatum (Rockville, USA) and C. Kollmannsberger (Vancouver, Canada)

10:15 Update on imaging tumor proliferation with PET 460
A. Shields (Detroit, USA)

10:40 Hypoxia imaging 461
K.A. Krohn (Seattle, USA)

11:05 Apoptosis imaging 462
H. Strauss (New York, USA)

11:30 Applications of nanotechnology and molecular probes in cancer imaging 463
T.J. Meade (Evanston, USA)

Plenary session 10 **Room ABC**

Abstract number

14:00–15:45 **Challenges in the development of antibodies and antibody conjugates**
Chairs: C.H. Takimoto (Radnor, USA) and J.M. Ford (Stanford, USA)

14:00 Antibodies/antibody conjugates in development 464
D. Chang (Thousand Oaks, USA)

14:25 Challenges in the development of antibody drug conjugates 465
S. Lutzker (South San Francisco, USA)

14:50 Challenges in targeting proteases as anti-cancer therapy 466
C. TenHoor (Cambridge, USA)

15:15 The targeted oncology platform at ImClone Systems: novel receptor blocking antibody therapeutics and approaches 467
E.K. Rowinsky (New York, USA)

Closing Ceremony **Room ABC**

15:45–15:50 Closing remarks

J. Doroshow	NCI
E.H. Rubin	AACR
P. Schöffski	EORTC

Poster Sessions

Antimetabolites Abstract number

The role of thymidine kinase and thymidylate synthase in the response of tumor cells to the suicide prodrug 2′-F-ara-deoxyuridine 468
P. Phatak, C.M. Daniels, A.F. Shields, J.M. Collins, P.M. LoRusso, A.M. Burger

The nucleoside analogue sapacitabine (CYC682) synergises with histone deacetylase inhibitors in multiple tumour types 469
I.N. Fleming, A.K. Choudhary, R.H. Mackay, S.R. Green, S. Davis

Target identification permits rational development of the prodrug GMX1777 for the treatment of melanoma 470
M. Watson, A. Roulston, H. Chan, D. Goulet, D. Bedard, E. Turcotte, G. Shore, J. Viallet, P. Beauparlant

Plasma pharmacokinetics of CP-4055 in patients with acute myeloid leukaemia at the recommended phase II dose 471
S. Hagen, S.M. O'Brien, T.F. Jacobsen, H.M. Kantarjian, M.L. Sandvold, F. Giles

The IMPDH inhibitor AVN944 synergizes with Clofarabine to induce cell death in myeloid cancer cell lines 472
J. Strovel, T. Lawrence, P. Natarajan, J.M. Hamilton, D.K. Bol

Bioreductive agents Abstract number

The bioreductive prodrug PR-104 is activated under aerobic conditions by human aldo-keto reductase 1C3 (prostaglandin F synthase) 473
A.V. Patterson, C.P. Guise, M. Abbattista, W. van Leeuwen, S.M. Pullen, D.M. Ferry, W.A. Denny, P. Guilford, W.R. Wilson

Relationships between reductive metabolism, DNA crosslinks and antitumor activity of the hypoxia-activated prodrug PR-104 in preclinical models 474
R.S. Singleton, S.M. Pullen, D.M. Ferry, C.P. Guise, A.V. Patterson, W.R. Wilson

Differentiation Abstract number

Sustained co-cultivation with human placenta-derived MSCs enhances ALK5/Smad3 signaling in human breast epithelial cells, leading to EMT and differentiation and inhibition of proliferation 475
Y.A. Young, M.H. Kang, J.S. Kim, J.H. Seo

Involvement of the helix-loop-helix protein ID-1 in granulocytic differentiation of human myeloblastic leukemia cells 476
T. Shimizu, K. Takeda

DNA repair Abstract number

Sequence-selective inhibition of the DNA binding potencies of Pit-1 and Brn-3 transcription factors by phenyl-furan-benzimidazole DNA ligands 477
P. Peixoto, S. Depauw, M.P. Hildebrand, D.W. Boykin, W.D. Wilson, M.H. David-Cordonnier

Human cancer cells are sensitized to voreloxin (formerly SNS-595) after modulation of DNA double strand break repair 478
R. Kimmel, J. Kumer, D. Stockett, R. Hawtin, P. Taverna, J. Silverman

Drug resistance and modifiers Abstract number

Monoclonal antibodies and targeted toxins/nuclides Abstract number

Radiation interactive agents Abstract number

RNA and RNA based technologies Abstract number

Signal transduction modulators Abstract number

Topoisomerase inhibitors Abstract number

Vaccines Abstract number